Product
ACY-241
2 clinical trials
2 indications
Indication
Lung CancerIndication
Multiple MyelomaClinical trial
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2024-01-22
Clinical trial
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-01-31